Terminated PHASE2 INTERVENTIONAL 1-arm NCT01325584

Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Hepatic Injury

Sponsor: Midwestern Regional Medical Center

Interventions Omegaven

Updated 9 times since 2017 Last updated: Jul 7, 2018 Started: Oct 31, 2012 Primary completion: Dec 31, 2016 Completion: Apr 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Alternative product is now approved and available for use.

Other terminated trials from Midwestern Regional Medical Center

Quality of Life · Phase PHASE1/PHASE2 · Mar 2017

More terminations from Midwestern Regional Medical Center

Other Cancer trials with similar outcome

Browse all Cancer trials

A PHASE2 clinical study on Cancer and Hepatic Injury, this trial is terminated or withdrawn. The trial is conducted by Midwestern Regional Medical Center and has accumulated 9 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Sep 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jul 2018 — Sep 2018 [monthly]

Terminated PHASE2

▶ Show 4 earlier versions

Jun 2018 — Jul 2018 [monthly]

Terminated PHASE2
Sep 2017 — Jun 2018 [monthly]

Terminated PHASE2
Feb 2017 — Sep 2017 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Midwestern Regional Medical Center

Data source: Midwestern Regional Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zion, United States